Literature DB >> 14698179

Design, synthesis, and activity of HDAC inhibitors with a N-formyl hydroxylamine head group.

Tom Y H Wu1, Christian Hassig, Yiqin Wu, Sheng Ding, Peter G Schultz.   

Abstract

Histone deacetylases (HDAC) are promising targets for cancer chemotherapy. HDAC inhibitors are thought to act in part by disrupting normal cell cycle regulation, resulting in apoptosis and/or differentiation of transformed cells. Several HDAC inhibitors, which contain hydrophobic tails and the Zn(2+) chelator hydroxyamic acid as a head group, are potent inhibitors of HDACs both in vitro and in vivo. In this study, a related class of compounds with a N-formyl hydroxylamino head group has been synthesized and their ability to inhibit HDACs have been assayed in biochemical and cellular assays. These compounds were found to have comparable activities to suberoylanilide hydroxyamic acid (SAHA) in HDAC enzymatic assays and histone hyperacetylation cellular assays.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14698179     DOI: 10.1016/j.bmcl.2003.10.055

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  6 in total

1.  Post-training intrahippocampal inhibition of class I histone deacetylases enhances long-term object-location memory.

Authors:  Joshua D Hawk; Cédrick Florian; Ted Abel
Journal:  Learn Mem       Date:  2011-05-16       Impact factor: 2.460

2.  Synthesis and biological evaluation of histone deacetylase inhibitors that are based on FR235222: a cyclic tetrapeptide scaffold.

Authors:  Erinprit K Singh; Suchitra Ravula; Chung-Mao Pan; Po-Shen Pan; Robert C Vasko; Stephanie A Lapera; Sujith V W Weerasinghe; Mary Kay H Pflum; Shelli R McAlpine
Journal:  Bioorg Med Chem Lett       Date:  2008-03-20       Impact factor: 2.823

3.  Synthesis and Pharmacological Evaluation of Selective Histone Deacetylase 6 Inhibitors in Melanoma Models.

Authors:  Maurício T Tavares; Sida Shen; Tessa Knox; Melissa Hadley; Zsófia Kutil; Cyril Bařinka; Alejandro Villagra; Alan P Kozikowski
Journal:  ACS Med Chem Lett       Date:  2017-09-05       Impact factor: 4.345

4.  Dynamic structure-based pharmacophore model development: a new and effective addition in the histone deacetylase 8 (HDAC8) inhibitor discovery.

Authors:  Sundarapandian Thangapandian; Shalini John; Yuno Lee; Songmi Kim; Keun Woo Lee
Journal:  Int J Mol Sci       Date:  2011-12-19       Impact factor: 5.923

5.  Exploration of Novel Inhibitors for Class I Histone Deacetylase Isoforms by QSAR Modeling and Molecular Dynamics Simulation Assays.

Authors:  Zainab Noor; Noreen Afzal; Sajid Rashid
Journal:  PLoS One       Date:  2015-10-02       Impact factor: 3.240

6.  Hyper-acetylation contributes to the sensitivity of chemo-resistant prostate cancer cells to histone deacetylase inhibitor Trichostatin A.

Authors:  Qingqing Xu; Xiaofei Liu; Shiqin Zhu; Xuelei Hu; Huanmin Niu; Xiulei Zhang; Deyu Zhu; Effat Un Nesa; Keli Tian; Huiqing Yuan
Journal:  J Cell Mol Med       Date:  2018-01-12       Impact factor: 5.310

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.